首页> 美国卫生研究院文献>Neuro-Oncology >DIPG-23. BRAINSTEM RADIATION EXPOSURE CONFERS SUBSTANTIAL RISK OF DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) IN MEDULLOBLASTOMA SURVIVORS: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY
【2h】

DIPG-23. BRAINSTEM RADIATION EXPOSURE CONFERS SUBSTANTIAL RISK OF DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) IN MEDULLOBLASTOMA SURVIVORS: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY

机译:DIPG-23。脑干辐射暴露导致髓母细胞瘤弥漫性内源性胶质神经胶质瘤(DIPG)的巨大风险:国际DIPG注册机构的报告

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

With improved survivorship in medulloblastoma, there has been increasing recognition of the occurrence of secondary malignant brain tumors. To date, no studies have specifically addressed the risk of diffuse intrinsic pontine glioma (DIPG) in medulloblastoma survivors. We queried the International DIPG Registry and identified six cases of DIPG with prior medulloblastoma. Six additional cases were identified in reports from recent cooperative group medulloblastoma trials. Incidence of DIPG after medulloblastoma ranged from 0.3–3.9%. All 12 cases underwent surgical resection followed by craniospinal photon irradiation (range 18–36 Gy) and posterior fossa boost (range 19.8–36 Gy). Posterior fossa exposure was greater than 53 Gy in all cases. Median time to diagnosis of secondary DIPG was 7 years (range 2–11 years). Patients died of secondary DIPG a median of 8 months after diagnosis (range 4–17 months). Molecular subgroup of primary medulloblastomas with available tissue (n=5) revealed only non-WNT, non-SHH subgroups (group 3 or 4). Tumor/germline exome sequencing of three secondary DIPGs demonstrated tumors to be H3.3 wildtype and harbor higher mutational burden than radiation-naïve DIPGs. Mutational signature analysis of secondary DIPGs showed mutations consistent with radiation-induced DNA damage (e.g., insertional event in TP53), as well as mutations in other oncogenic drivers (e.g., NRAS, PI3KCA), suggestive of distinct mutational processes compared with primary DIPGs. In conclusion, we report for the first time that survivors of pediatric medulloblastoma are at risk for the development of secondary DIPG, likely consequent to radiation exposure. This risk highlights the importance of radiation field, volume, and modality in medulloblastoma treatment.
机译:随着髓母细胞瘤存活率的提高,人们对继发性恶性脑肿瘤的发生的认识日益增加。迄今为止,尚无任何研究专门针对髓母细胞瘤幸存者中弥漫性桥脑神经胶质瘤(DIPG)的风险。我们查询了国际DIPG注册中心,并确定了6例DIPG伴有髓母细胞瘤的病例。最近的合作组髓母细胞瘤试验报告中还发现了另外6个病例。髓母细胞瘤后DIPG的发生率为0.3-3.9%。所有12例均接受外科手术切除,随后进行颅骨脊髓光子照射(范围18–36 Gy)和后颅窝增强(范围19.8–36 Gy)。在所有情况下,后颅窝暴露均大于53 Gy。二次DIPG诊断的中位时间为7年(范围2-11年)。患者在诊断后中位数为8个月(4-17个月),死于继发性DIPG。具有可用组织的原发性髓母细胞瘤的分子亚组(n = 5)仅显示非WNT,非SHH亚组(第3或4组)。三种次生DIPG的肿瘤/种系外显子组测序结果表明,该肿瘤为H3.3野生型,比未接受过辐射的DIPG具有更高的突变负担。次要DIPG的突变特征分析显示,突变与辐射诱导的DNA损伤一致(例如TP53中的插入事件),以及其他致癌驱动因子(例如NRAS,PI3KCA)的突变,提示与主要DIPG相比明显的突变过程。总之,我们首次报告小儿髓母细胞瘤的幸存者有继发DIPG的风险,这很可能是由于辐射暴露所致。这种风险凸显了在髓母细胞瘤治疗中辐射场,体积和模态的重要性。

相似文献

  • 外文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号